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ABSTRACT 
 
The cleavage of target mRNA by ribozymes is being exploited as a means of gene silencing in nucleic-acid-
based therapies. We previously established an HIV-1-dependent ribozyme-expression vector system, based on 
Cre-loxP technology with an LTR-gag-p17 promoter as a molecular switch for use in acute HIV-1 infection. 
The simultaneous expression of the Cre protein and loxP homologous recombination induced a high level of 
HIV-1-replication inhibition, but ribozyme expression was transient. In the current study, we overcame this 
limitation by inserting EBNA-1 and oriP genes from the Epstein-Barr virus (EBV) into the vector. When this 
plasmid was introduced into HeLa CD4
+ cells, we observed long-term expression of both the EGFP reporter 
gene and the ribozyme. Moreover, HIV-1 replication was inhibited in the long-term in transfected cells. These 
data suggest that the HIV-1-dependent ribozyme-expression vector containing EBNA-1/oriP sequences would 
be a useful tool in HIV-1 gene therapy applications. 
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INTRODUCTION 
 
In  the  application  of  therapeutics  to  HIV-1  infection, 
prevention is of greater importance than treatment. With 
this aim, many antiviral RNA-expression vector systems 
have been developed for use in anti-HIV-1 gene therapy 
(Banerjea  et  al,  2003;  Barnor  et  al,  2004;  Boden  et  al, 
2004; Cordelier P et al, 2004; Habu et al, 2005; Mautino 
and Morgan, 2002; Takaku, 2004). Recently, small RNA 
molecules such as, siRNAs and snRNAs, have also been 
shown  to  affect  gene  silencing  by  RNA  interference 
(Boden et al, 2003; Chang et al, 2002; Li et al, 2003). 
Increasing  the  efficiency  of  transgene  expression  is  of 
prime  importance  for  human  gene  therapy  (Davis  and 
McNeilly,  2001).  The  Epstein-Barr  Virus  (EBV)  is  an 
autonomously replicating episomal vector that has been 
utilized to overcome the problem of rapid elimination of 
intracellularly delivered plasmid DNA in nonviral gene 
transfer. EBV is a gammaherpesvirus that is maintained 
as an episome of approximately 172 kb in size in a small 
number of resting B cells and epithelial cells in most of 
the human population. It latently infects human B cells 
with  a  high  efficiency,  after  which  its  linear  double-
stranded genome circularizes and is sustained as a stable  
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episome  (Hirai  and  Shirakata,  2001).  The  EBV 
replication system is present at a frequency of about 1-
100  copies  per  cell,  and  maintains  a  non-covalent 
attachment to the host chromosome. 
 
The  latent  origin  of  replication  oriP  and  the  viral 
transactivator  protein  EBNA-1  are  essential  components 
for  EBV latent  replication and  maintenance  of  the  viral 
genome  (Daikoku  et  al,  2004;  Lee  et  al,  1999).  Both 
elements  have  been  employed  for  long-term  transgene 
expression  in  gene-therapy  studies  (Otomo  et  al,  2001; 
Tsujie et al, 2001). 
 
Previously, we described an HIV-1-dependent ribozyme-
expression  vector  capable  of  achieving  site-specific 
excision of loxP sequences by using the HIV-1 minimal 
LTR-Cre-loxP system as a molecular switch in an acute 
HIV-1 infection (Habu et al, in press). However, we were 
unable to  detect  long-term expression of the anti-HIV-1 
ribozyme.  We  hypothesized  that  the  length  of  HIV-1-
dependent  transgene  expression  could  be  significantly 
increased  in  mammalian  cells  by  introducing  EBNA-
1/oriP sequences to the vector. 
 
In this study, we constructed an HIV-1-dependent long-
term transgene (RNA ribozyme) expression vector (LTR-
gag-p17/Cre-loxP-Rz-U5-EBNA-1-oriP-EGFP  (EOG)) 
using the EBV replicon system, which was propagated in 
Escherichia coli and transfected into mammalian cells. We 
measured transgene-expression levels, including EBNA-1 
and oriP, in the presence and absence of HIV-1 infectious 
molecular  clone  (pNL4-3,  Adachi  et  al,  1986).  The 
potential anti-HIV-1 activity of the expression vector was 
evaluated with  a  view  to  establishing a  highly  effective 
therapeutic agent that could be further developed for HIV 
gene-therapy applications. 
 
MATERIALS AND METHODS 
 
Construction of plasmids 
The retroviral vector pLEGFP-C1 (Clontech, Mountain 
View, CA) was digested with Nhe I and Xho I to release 
the DNA fragment encoding enhanced green fluorescent 
protein (EGFP). This was inserted into the Nhe I/Xho I 
sites  of  pCEP4  (Invitrogen,  Carlsbad,  CA),  which 
contains EBNA-1 and oriP, to create pCEP4-EGFP. An 
Ssp I fragment containing EGFP, EBNA-1, and oriP was 
cloned into the Stu I sites of pLTR-gag-p17-Cre/loxP-
Rz-U5 (Habu et al, in press) and  ploxP-Rz-U5, which 
been previously described with a high cleavage affinity 
(Habu et al, 2002) to yield pLTR-gag-p17-Cre/loxP-Rz-
U5-EOG  (Figure  1A)  and  ploxP-Rz-U5-EOG  (Figure 
1C), respectively. The control plasmid vector ploxP-Rz-
U5-EOG lacks the LTR-gag-p17-Cre gene and so does 
not  trigger  expression  of  the  ribozyme.  A  Pvu  II 
fragment  containing  the  EGFP-expression  unit  was 
excised  from  pCMV-EGFP  previously  constructed 
(unpublished  data)  and  cloned  into  the  Stu  I  sites  of 
ploxP-Rz-U5  (Habu  et  al,  2002)  or  pLTR-gag-p17-
Cre/loxP-Rz-U5 to generate ploxP-Rz-U5-G (Figure 1D) 
and  pLTR-gag-p17-Cre/loxP-Rz-U5-G  (Figure  1B), 
which  are  the  EBNA-1  and  oriP  negative-control 
plasmids, respectively. 
Cell culture and transfections 
HeLa  CD4
+  cells  were  grown  in  RPMI  1640  medium 
(Sigma, Saint Louis, MO) supplemented with 10% (v/v) 
heat-inactivated FBS, 100 U/ml penicillin, and 100 µg/ml 
streptomycin.  HEK  293T  cells  were  grown  in  DMEM 
containing 10% FBS, 100 U/ml penicillin, and 100 µg/ml 
streptomycin. All cells were maintained at 37 °C in a 5% 
CO2 atmosphere. HeLa CD4
+ and 293T cell transfections 
were carried out using FuGENE™6 (Roche Diagnostics, 
Basel,  Switzerland)  according  to  the  manufacturer’s 
protocol. 
 
Luciferase assay 
Luciferase  activity  was  measured  with  the PicaGene  kit 
(Toyo-inki, Tokyo, Japan) according to the manufacturer’s 
protocol. The target gene-expressing plasmid pNL4-3-luc 
(Akkina et al, 1996), lacking an env gene and with a firefly 
luciferase gene replacing the nef gene, was co-transfected 
into HeLa CD4
+ cells with the pLTR-gag-p17-Cre/loxP-
Rz-U5-EOG  plasmid,  which  expresses  the  ribozyme 
following  Cre/loxP  homologous  recombination. 
Transfected  HeLa  CD4
+  cells  were  lysed  in  200  µl 
PicaGene cell lysis buffer for 15 min and then harvested. 
Cell  debris  was  removed  by  centrifugation.  Centrifuged 
lysate (10 µl) was added to 100 µl luminous substrate, and 
the luminescent signal was immediately quantitated with a 
luminometer  (Lumat  LB  9507;  Berthold,  Bad  Wildbad, 
Germany). 
 
Flow cytometry 
Transfected  HeLa  CD4
+  cells  were  trypsinized,  washed 
twice  in  PBS,  and  fixed  in  PBS  containing  1% 
formaldehyde. Direct fluorescence of EGFP was analyzed 
by  FACS  Calibur  (Clontech).  Data  acquisition  and 
analysis  were  performed  with  CellQuest  software 
(Clontech). Gates for detection of EGFP were established 
using mock-transfected cells as background. 
 
Fluorescent microscopy 
To  evaluate  the  self-replicating  function  of  the  loxP 
ribozyme as an index for stable transgene expression in 
cells, transfected HeLa CD4
+ cells were trypsinized and 
seeded  at  a  low  cell  density.  Direct  fluorescence 
microscopy of EGFP was carried out at the mitotic stage 
of cell division, after each passage on days 1, 3, 7, 13, 19 
and  25 and  the  data were acquired with a  DP12  digital 
microscope camera (Olympus Company, Tokyo, Japan). 
 
RNA isolation and RT-PCR 
Total  cellular  RNA  was  isolated  from  transfected  HeLa 
CD4
+ cells with the GenElute Mammalian Total RNA kit 
(Sigma) using the manufacturer’s protocol. RNA samples 
were  treated  with  DNase  I  (Promega,  Madison,  WI) 
according  to  the  manufacturer’s  instructions.  RT-PCR 
assays were carried out using previously described primers 
(Habu et al, 2002) and the RT-PCR high-Plus-kit (Toyobo, 
Osaka, Japan) according to the manufacturer’s protocol. 
 
Assay of HIV-1 replication 
HIV-1 production was monitored by determining the HIV-
1  p24  antigen  concentration.  The  culture  medium  from 
HeLa CD4
+ cells co-transfected with pNL4-3 and pLTR-
gag-p17-Cre/loxP-Rz-U5-EOG was harvested on days 1,  
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3, 5, 7, 9, 11, 13 and 15 post-transfection. p24 Gag protein 
production was detected by the HIV-1 p24 CLEIA assay 
(Lumipulse, Fujirebio Inc., Tokyo, Japan),
 according to the 
manufacturer’s protocol (Sakai et al, 1999). 
 
RESULTS AND DISCUSSION 
 
Design and construction of an HIV-1-dependent Cre-
expression vector 
Tissue-specific gene transfer and expression are crucial 
for the development of safe and effective gene-therapy 
protocols. To this end, the HIV-1 LTR can serve as an 
efficient and inducible promoter dependent on the HIV-1 
trans-activation  factor,  Tat.  In  a  previous  study,  we 
constructed  the  HIV-1-dependent  RNA  ribozyme 
expression Cre/loxP vector, pLTR-gag-p17-Cre/loxP-Rz-
U5-G, which targets mRNAs encoded by the U5 region 
(548–578) of the LTR (Figure 1E). This vector showed 
HIV-1-dependent  ribozyme  expression  in  HeLa  CD4
+ 
cells  (Habu  et  al,  2002;  Habu  et  al,  in  press),  but 
expression  was  not  long  term.  Hence,  in  the  current 
study,  we  constructed  an  HIV-1-dependent  expression 
vector containing Cre/loxP and EBNA-1/oriP sequences, 
with  the  aim  of  increasing  the  duration  of  transgene 
expression.  Moreover,  we  inserted  the  reporter  gene 
EGFP  to  enable  visualization  of  transgene  expression 
(Figure  1A).  The  plasmid  vectors  pLTR-gag-p17-
Cre/loxP-Rz-U5-G  (Figure  1B),  ploxP-Rz-U5-EOG 
(Figure 1C), and ploxP-Rz-U5-G (Figure 1D) served as 
controls.  The  advantage  of  this  vector  system  over 
previously reported ribozyme vector systems (Chang et 
al, 2002;  Li et al,  2003) is  that it is not constitutively 
expressed  to  trigger  off  non-specific  inhibition,  but 
specifically expressed only in the event of HIV infection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Schematic representation of HIV-1-dependent ribozyme-expression vectors. (A) The ribozyme expression (off switch) 
vector pLTR-gag-p17-Cre/loxP-Rz-U5-EOG, containing EBNA-1 and oriP genes for long-term expression. (B) Control 
ribozyme-expression vector pLTR-gag-p17-Cre/loxP-Rz-U5-G, which lacks EBNA-1 and oriP genes. (C) Control vector ploxP-
Rz-U5-EOG, which lacks the LTR-gag-p17-Cre gene. (D) Control vector ploxP-Rz-U5-G, which lacks EBNA-1/oriP and LTR-
gag-p17-Cre genes. (E) HIV-1 NL4-3 molecular clone pNL4-3-luc containing the luciferase reporter gene, showing the target site 
and structure of the constructed ribozyme.
A B
D C
E
A B
D C
E 
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Long-term  transgene  expression  of  pLTR-gag-p17-
Cre/loxP-Rz-U5-EOG in 293T and HeLa CD4
+ cells 
To characterize the ability of the EBV replication system 
to  effect  long-term  transgene  expression  we  compared 
EGFP  expression  of  control  vector  (pLTR-gag-p17-
Cre/loxP-Rz-U5-G) with that of the EBNA-1/oriP plasmid 
pLTR-gag-p17-Cre/loxP-Rz-U5-EOG.  EGFP  expression 
in  pLTR-gag-p17-Cre/loxP-Rz-U5-G-transfected  293T 
cells was observed for a maximum of 3 days, while EGFP 
expression persisted for more than 25 days in pLTR-gag-
p17-Cre/loxP-Rz-U5-EOG-transfected 293T cells (Figure 
2).  As  it  has  been  reported  that  the  EBNA-1  protein 
potentiates gene transcription (Mackey and Sugden, 1999), 
we  measured  the  enhancement  of  gene  expression  by 
determining EGFP fluorescence intensity. FACS analysis 
showed that HeLa CD4
+ cells transfected with the EBNA-
1-containing  plasmids  demonstrated  longer-term  EGFP 
expression (until day 7; Figure 3) than HeLa CD4
+ cells 
transfected  with  plasmids  lacking  EBNA-1.  This  is  of 
therapeutic  importance,  because  EBNA  retains  the 
therapeutic  molecule  to  sensor  for  infective  HIV-1  to 
release the catalytic ribozyme for cleavage. 
 
Measurement  of  the  mean  fluorescence  intensity  (MFI) 
revealed a twofold increase in the EGFP expression level 
of  HeLa  CD4
+  cells  transfected  with  pLTR-gag-p17-
Cre/loxP-Rz-U5-EOG  compared  with  pLTR-gag-p17-
Cre/loxP-Rz-U5-G-transfected  cells  (data  not  shown). 
These  results  indicate  that  EBNA-1/oriP  sequences 
mediate  efficient  and  stable  replication  of  transgene 
expression by enhancing nuclear localization of EBNA-1 
(Mackey and Sugden, 1999; Marechal et al, 1999). The 
nuclear  localization  of this  vector system is  of cardinal 
importance  since  its  function  is  induced  by  HIV-1  tat 
which is nuclear-based. 
 
Dose-dependent  inhibition  of  HIV-1  replication  by 
pLTR-gag-p17-Cre/loxP-Rz-U5-EOG 
The  effect  of  pLTR-gag-p17-Cre/loxP-Rz-U5-EOG  on 
HIV-1  (pNL4-3-luc)  replication  was  measured  in  a 
transient assay following its co-transfection with pNL4-3-
luc into HeLa CD4
+ cells. At 72 h post-transfection, the 
luciferase  activity  of  cell  lysate  was  measured  as  an 
indirect marker  of viral  replication.  The  plasmid vector 
ploxP-Rz-U5-EOG  (Figure  1C),  which  does  not  trigger 
ribozyme  expression  as  it  lacks  the  LTR-gag-p17-Cre 
gene, was used as a control. Our analysis showed a dose-
dependent inhibition of HIV-1 replication by pLTR-gag-
p17-Cre/loxP-Rz-U5-EOG  with  a  maximum  inhibitory 
efficacy of >90% at a vector DNA concentration of 1.67 
µg  (Figure  4).  Control  vector  alone  had  no  inhibitory 
effect. This result suggests that the Rz-U5 ribozyme was 
expressed using Cre/loxP recombination and EBNA/oriP 
systems in HIV-1 infected cells, and successfully cleaved 
its target HIV-1 mRNA (Figure 1E). 
 
EBNA-1  mediates  long-term  ribozyme  expression  in 
HIV-1-dependent vector-transfected HeLa CD4
+ cells 
As  long-term  ribozyme-U5  (Rz-U5)  expression  is  an 
important determinant of its efficiency, we compared the 
level of expression in HeLa CD4
+ cells transfected with 
pLTR-gag-p17-Cre/loxP-Rz-U5-EOG  or  pLTR-gag-p17-
Cre/loxP-Rz-U5-G in the presence or absence of pNL4-3 
(Figure  5).  RT-PCR  analysis  showed  that  Rz-U5 
expression  persisted  for  more  than  19  days  following 
pLTR-gag-p17-Cre/loxP-Rz-U5-EOG  transfection  in  the 
absence  of  pNL4-3  (Figure  5).  By  contrast,  pLTR-gag-
p17-Cre/loxP-Rz-U5-G-transfected cells demonstrated Rz-
U5 expression for only 3 days. Ribozyme expression was 
not  observed  following  transfection  of  either  plasmid 
DNA in the absence of pNL4-3. These results confirm that 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. EBNA-1 and oriP increase the duration of EGFP expression in transfected HeLa CD4
+ and 293T cells. EGFP 
expression was evaluated on days 1, 3, 7, 13, 19, and 25 post-transfection. 
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Figure 3. Enhancement of transgene expression by EBNA-1 and oriP in HeLa CD4
+ cells. EGFP expression was evaluated on 
days 1 to 7 post-transfection by flow cytometry. 
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Figure 4. Dose-dependent inhibition of HIV-1 replication by pLTR-gag-p17-Cre/loxP-Rz-U5-EOG in HIV-1-transfected cells. 
Different amounts of pLTR-gag-p17-Cre/loxP-Rz-U5-EOG (0.17, 0.83 or 1.67 µg) were co-transfected with HIV-1 (pNL4-3-
luc) into HeLa CD4
+ cells. At 72 h post-transfection, luciferase activity of the cell lysate was measured as an indirect marker for 
viral replication. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. RT-PCR analysis shows persistent ribozyme expression of HeLa CD4
+ cells transfected with EBNA-1/oriP-containing 
vector. Total RNA was isolated from confluent pNL4-3 infected cell cultures transfected with pLTR-gag-p17-Cre/loxP-Rz-U5-G or 
pLTR-gag-p17-Cre/loxP-Rz-U5-EOG. RT-PCR using ribozyme-specific primers was performed concurrently with amplification of 
GAPDH mRNA. 
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the Cre/loxP vector containing EBNA-1 has the potential to 
confer  long-term  transgene  expression  in  HIV-1  infected 
cells. This property therefore puts our vector system in the 
class  of  prophylactics,  since  the  vector  will  function  to 
prevent infection of the target cells.  
 
Long-term inhibition of HIV-1 replication by pLTR-gag-
p17-Cre/loxP-Rz-U5-  EOG  in  pNL4-3  infected  HeLa 
CD4
+ cells 
To  evaluate  further  the  persistency  of  the  EBNA-1/oriP-
dependent  ribozyme  effect  on  HIV-1  replication  we  co-
transfected  0.3  µg  pNL4-3  with  5.0  µg  pLTR-gag-p17-
Cre/loxP-Rz-U5-EOG,  pLTR-  gag-p17-Cre/loxP-Rz-U5-G 
or ploxP-Rz-U5-EOG into HeLa CD4
+ cells. As shown in 
Figure  6A,  pLTR-gag-p17-Cre/loxP-Rz-U5-EOG  inhibited 
HIV-1 replication for 15 days. By contrast, ploxP-Rz-U5-
EOG (lacking ribozyme expression) showed little inhibitory 
activity  towards  HIV-1  replication  compared  with  the 
negative control (pNL4-3 only). 
 
EGFP  reporter  gene  expression  was  monitored  as  an 
indicator of transgene expression (Figure 6B). Its persistence 
throughout  the   experiment  (up  to  13  days)  confirms  our 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Inhibitory effects on HIV-1 p24 antigen production by 
pLTR-gag-p17-Cre/loxP-Rz-U5-EOG. (A) HeLa CD4
+ cells 
were co-transfected with HIV-1 pNL4-3 and either control vector 
(diamonds), ploxP-Rz-U5-EOG (squares), pLTR-gag-p17-
Cre/loxP-Rz-U5-G (triangles), or pLTR-gag-p17-Cre/loxP-Rz-
U5- EOG (circles). HIV-1-virus production was measured by p24 
ELISA at the indicated times post-transfection. (B) Transgene 
replication in dividing cells. Cells were passaged every 2 days, 
and monitored for transgene replication by way of EGFP 
expression in singly dividing cells. 
earlier  findings,  and  suggests  that  the  HIV-1-dependent 
ribozyme-expression  vector  containing  EBNA-1/oriP 
sequences mediates long-term ribozyme expression, inhibits 
HIV-1  replication  and  would  be  a  useful  tool  for  HIV-1 
gene-therapy applications. 
 
CONCLUSIONS 
 
• Ribozyme expression is HIV-1 Tat dependent, as we 
were only able to detect it in the presence of pNL4-3. 
 
• Transgene expression  is  long-term  and is  extended 
by  the  presence  of  oriP  and  EBNA-1.  Hence, 
inhibition is also shown to be long-term. 
 
• The  Cre/loxP  system  induces  ribozyme-mediated 
inhibition of HIV-1 replication in a dose-dependent 
manner. 
 
• These  results  demonstrate  the  anti-HIV-1  effect  of  the 
expressed  ribozyme  from  the  Cre/loxP  system,  clearly 
illustrating  the  potential  of  the  Cre/loxP-oriP/EBNA-1 
system  as  a  gene-therapy  tool  for  controlling  HIV-1 
infection. 
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